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Introduction
The current World Health Organisation (WHO) classifica-
tion for hematopoietic neoplasms enables the accurate diag-
nosis of most lymphoma types. Some problem areas, howev-
er, remain, one of which is the diagnosis of nodal marginal
zone lymphoma (NMZL). The identification of NMZL has
been difficult because of the rarity of this disease and the lack
of positive immunohistochemical or molecular markers. As a
result, epidemiology, prognosis, and therapeutic options have
not been firmly established. In this review, we provide an
overview of the current knowledge on NMZL with special
emphasis on diagnostic criteria and pathogenesis, based on a
systematic review of the literature.
We performed a PubMed search in October 2012 with the
key words “NODAL MARGINAL ZONE LYMPHOMA”,
“MONOCYTOID B-CELL LYMPHOMA”, “NODAL MZL”,
and “NODAL MZLS”, and filtered for publications in the
English language. After removal of duplicates, 167 hits were
retrieved, including articles from 1986 until 2012. Only arti-
cles published after 1994 were included, coinciding with the
adoption of the REAL classification, after which NMZL and
extranodal MZL (EMZL) became more clearly separated in lit-
erature. From the remaining 116 articles, the abstracts of all
articles were read by one of the authors (MvdB). Twenty-five
papers were excluded because they dealt with EMZL or other
entities, and four papers were excluded because NMZLs rep-
resented only a very minor part of a larger series (i.e. only 1
or 2 cases of NMZL, comprising less than 10% of cases). The
remaining 87 papers were read in their entirety, and included
if deemed relevant for this review. Additional papers were
included from bibliographies. 
Classification of NMZL
According to the current (2008) WHO classification, NMZL
is “a primary nodal B-cell neoplasm that morphologically
resembles lymph nodes involved by MZL of extranodal or
splenic types, but without evidence of extranodal or splenic
disease”.1 This means that for a diagnosis of NMZL, integra-
tion of clinical and pathological data is required. It also
implies that NMZL is a diagnosis of exclusion. Also, this def-
inition has resulted in putting the three categories together
into one larger group, thus obscuring the important differ-
ences between them.
Marginal zone lymphomas were initially classified as
‘monocytoid B-cell lymphomas’. This term was put forward
by Sheibani et al. in 1986 in a paper describing lymphomas
consisting of cells that resemble the monocytoid B-cells
observed in reactive conditions like lymphadenitis in toxo-
plasmosis and HIV lymphadenopathy.2 At that time, there
was no strict separation between nodal and extranodal MZLs.
The revised Kiel classification from 1990 introduced the sep-
aration between nodal and extranodal marginal zone lym-
phoma (EMZL).3 Shortly thereafter, multiple papers empha-
sized the morphological similarities between EMZL (at that
time referred to as MALT lymphoma, i.e. lymphoma of the
mucosa associated lymphoid tissue) and NMZL.4,5 In the
REAL classification of 1994, and in the 2001 WHO classifica-
tion, NMZL was adopted as a provisional entity.6,7 In the cur-
rent 2008 WHO classification, NMZL has become a definitive
entity and a pediatric variant has been included.
It has not been firmly established whether MZL of
Waldeyers ring should be considered NMZL or EMZL. A
recent Korean study suggests that, because of the overlap in
prognosis, MZL of Waldeyers ring resembles NMZL rather
than EMZL.8
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The diagnosis of nodal marginal zone lymphoma is one of the remaining problem areas in hematopathology. Because
no established positive markers exist for this lymphoma, it is frequently a diagnosis of exclusion, making distinction
from other low-grade B-cell lymphomas difficult or even impossible. This systematic review summarizes and dis-
cusses the current knowledge on nodal marginal zone lymphoma, including clinical features, epidemiology and eti-
ology, histology, and cytogenetic and molecular features. In particular, recent advances in diagnostics and pathogen-
esis are discussed. New immunohistochemical markers have become available that could be used as positive markers
for nodal marginal zone lymphoma. These markers could be used to ensure more homogeneous study groups in
future research. Also, recent gene expression studies and studies describing specific gene mutations have provided
clues to the pathogenesis of nodal marginal zone lymphoma, suggesting deregulation of the nuclear factor kappa B
pathway. Nevertheless, nodal marginal zone lymphoma remains an enigmatic entity, requiring further study to
define its pathogenesis to allow an accurate diagnosis and tailored treatment. However, recent data indicate that it is
not related to splenic or extranodal lymphoma, and that it is also not related to lymphoplasmacytic lymphoma. Thus,
even though the diagnosis is not always easy, it is clearly a separate entity. 
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Epidemiology and etiology
NMZL is a rare lymphoma, accounting for 1.5-1.8% of
lymphoid neoplasms.9,10 The incidence of NMZL appears
to be increasing, which is most likely due to a ‘real’
increase, rather than better recognition.11 Most studies
report a median age around 60 years with a wide age dis-
tribution ranging from adolescence to patients over 90
years old.9-20 Both sexes are affected with approximately
equal frequency.
Morphologically, NMZL resembles EMZL. EMZL is
well known for its association with conditions that pro-
vide a chronic stimulation to the immune system, includ-
ing chronic infections (e.g. Helicobacter pylori infection in
gastric EMZL) and autoimmune conditions (e.g. salivary
gland EMZL in Sjögren’s syndrome). From this, one could
hypothesize that NMZL, or a subset of NMZLs, might
also be caused by specific chronic inflammatory condi-
tions. Indeed, infections and autoimmune disorders have
been reported in association with NMZL, but this evi-
dence remains far from sufficient to establish a definitive
role for these stimuli in lymphomagenesis. Recently, we
encountered a case of what we had referred to as NMZL
lymphoma in an axillary lymph node. However, we
detected H. pylori by PCR analysis and a gastric biopsy
revealed EMZL. This case implies that without extensive
workup, including gastric biopsies, one cannot be sure
that a case of NMZL really represents this entity.
Hepatitis C virus (HCV) has been reported in a subset of
NMZL patients. In an early but small study, monocytoid
B-cell lymphoma had the highest prevalence of HCV in
comparison with other lymphoma types.21 In a larger
study by Arcaini et al.,9 of 38 (24%) patients with NMZL
had positive serology for HCV, in one patient combined
with positive hepatitis B virus (HBV) serology.16 Some
other studies confirmed an association with HCV in a
smaller proportion of patients (Camacho et al. and Oh et al.
in 20% and 5%, respectively),13,14 but other studies did
not.15 The study by Camacho et al. also showed HBV
infection in 30% of patients. The difference in HCV preva-
lence in NMZL between studies might be caused by geo-
graphical variation, which also appears to hold true for
HCV prevalence in lymphoplasmacytic lymphoma, an
entity closely related to NMZL.22-25
NMZL has also rarely been described in human immun-
odeficiency virus-infected patients, and complete regres-
sion of transformed NMZL has been reported in one such
patient after anti-retroviral therapy.26,27
The composition and use of the different variable fami-
lies on the immunoglobulin heavy chain locus have been
connected to certain diseases in specific lymphoma types.
In NMZL, multiple studies have shown biased use of
immunoglobulin heavy chain VH families VH3 and VH4,
in particular VH4-34.13,15,28-31 Preferential use of VH3-34 is
associated with Epstein-Barr virus and cytomegalovirus in
patients with chronic lymphocytic leukemia.32 In NMZL,
an association with these viruses has not been
established.13,33,34 In NMZL patients with HCV, VH1-69
was used preferentially, which is in line with other studies
that describe the preferential use of VH1-69 in response to
the E2 antigen of HCV.31,35
Many studies have reported autoimmune diseases in
association with NMZL and include rheumatoid arthritis,
vitiligo, systemic lupus erythematosus, autoimmune
hemolytic anemia, chronic thyroiditis, and Sjögren’s syn-
drome.16-18 In these studies, 6-19% of patients had an
autoimmune disease. To summarize, there are indications
that NMZL is associated with chronic inflammation, but
the precise mechanisms remain unknown. 
Clinical and laboratory features of patients with NMZL
The clinical features at presentation are summarized in
Table 1.9-11,13-19 Most patients with NMZL present with
peripheral lymphadenopathy; a very small minority of
patients have only central lymphadenopathy at presenta-
tion. The head and neck lymph nodes are most frequently
involved. Bulky tumors (> 5 cm) are observed in 11-31%
of patients. Across studies, roughly half the patients pres-
ent with stage III or IV disease and 10-20% of patients
experience B symptoms. Anemia is present with varying
frequency (11-36%).9,14-16,18 If these studies are taken
together, approximately one quarter of patients are ane-
mic. Thrombocytopenia has been described in one study
in one-tenth of patients.15 Involvement of the peripheral
blood is reported in 10-24% of patients.9,13,15,16 The inci-
dence of bone marrow involvement varies greatly
between studies (from 0-62%), but an overall appraisal of
the data shows that the bone marrow is involved in
approximately one-third of patients.9,10,13-18,38
Positron emission tomography (PET) using (18)F-fluo-
rodeoxyglucose appears to be a good way to study disease
extent in NMZL, considering the PET-positivity in the
large majority of cases reported so far (92% of 14
cases).39,40
Serum lactate dehydrogenase (LDH) is elevated in 12-
48% of patients, beta 2 (b2)-microglobulin is increased in
29-45%.9,10,13-19 An M-component is present in 6-33% of
patients.9,15-17 In one study, cryoglobulins were present in
only 2 of 14 patients.15 Hypoalbuminemia was reported in
7-10% in two studies.9,15
To summarize, the clinical presentation of NMZL is
non-specific and highly variable, but this may be due to
the difficulty of the diagnosis and the variable rigor by
which other entities have been excluded. 
Cell of origin
Marginal zone lymphoma receives its name from the
resemblance to the physiological marginal zone. The mar-
ginal zone surrounds the mantle zone of the germinal cen-
ter and is usually not recognized morphologically in
lymph nodes. However, the spleen and some mesenteric
lymph nodes do show a marginal zone in normal situa-
tions, and, occasionally, other lymph nodes also have mar-
ginal zone development.41
NMZL arises from mature B cells that have rearranged
immunoglobulin genes, and can, therefore, be detected in
clonality studies. However, the precise B-cell of origin of
NMZL remains poorly defined and it has been suggested
that NMZL can arise from different subsets of mature B
cells, not necessarily being marginal zone B cells. Multiple
small studies have examined the presence of somatic
hypermutation (SHM), which was detected in the large
majority of cases (in approximately 85%),13,15,28-31,42 suggest-
ing a (post-)germinal center B cell. However, less than half
the cases showed evidence of antigen selection. The study
by Conconi and colleagues showed ongoing mutations in
4 of 6 hypermutated cases, suggesting derivation from ger-
minal center B cells.30 Although the presence of SHM sug-
gests post-germinal center derivation, there is accumulat-
ing evidence for germinal center-independent SHM. This
evidence comes from patients with hyper-IgM syndrome
M. van den Brand et al.
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and X-linked lymphoproliferative disorder, who lack func-
tional germinal centers, but do show some SHM.43,44
Multiple other studies have also shown germinal center-
independent SHM.45,46 Very recently, Warsame and associ-
ates showed evidence of ongoing mutations in microdis-
sected monocytoid B cells.47 In addition, these cells
expressed activation-induced cytidine deaminase, which
is required for SHM.
The name NMZL suggests derivation from marginal
zone cells, and the expression of MNDA and IRTA1 in
many cases (see below) supports this notion; the data so
far are, however, still conflicting.
Histopathology
NMZL has great variability in growth pattern and cellu-
lar morphology and is, therefore, almost never a ‘spot
diagnosis’. Rather, a diagnosis of NMZL requires careful
integration of morphology, immunohistochemistry,
molecular studies, and clinical features (Figure 1).
On low power, multiple growth patterns can be recog-
nized, as was nicely illustrated by Salama and colleagues.48
In their study, a diffuse pattern of infiltration was most
frequent (in 31 of 51 cases), followed by interfollicular and
nodular patterns of infiltration in 14% and 10%, respec-
tively. Perifollicular growth was reported in only one case.
In a study by Traverse-Glehen et al. of 21 patients, nodular
and interfollicular growth was most frequently observed,
both in one-third of patients.15 Five cases showed diffuse
growth; 2 showed an inverse follicular pattern.
On high power, NMZL cells show heterogeneous mor-
phology, varying from centrocyte-like cells to monocytoid
cells to plasmacytoid cells and plasma cells with varying
numbers of interspersed centroblasts and immunoblasts.
Monocytoid cells have a central nucleus with condensed
chromatin and indistinct nucleoli, surrounded by ample
pale cytoplasm. Centrocyte-like cells, resembling the cen-
trocytes of the germinal center, have nuclei with slightly
irregular nuclear membranes and a coarser chromatin
structure. Lymphoplasmacytoid cells have some, but not
all features of plasma cells; in comparison to plasma cells
they have less cytoplasm that is basophilic. They are
smaller than typical ‘Marschalko-type’ plasma cells and
have a finer chromatin structure. Monocytoid cells were
reported in one-third of cases in one study,15 but predom-
inance of monocytoid cells is rare and should prompt con-
sideration of secondary lymph node involvement by
MALT lymphoma.49 Plasmacytic differentiation has been
reported in 22-47%13,15,48,50 and can be extensive (Figure 1G-
I). Dutcher bodies are rarely observed, but can be numer-
ous.15,50 One case of NMZL with Auer-rod-like inclusions
has been reported.51
Campo et al. classified growth patterns in NMZL into
splenic and MALT type, which has subsequently become
the subject of debate.52,53 The splenic type, being present in
6 of 36 cases, was described as consisting of a polymor-
phic infiltrate around residual germinal centers that lack a
clear mantle cuff. The remainder of the cases were of the
MALT type, characterized by perisinusoidal and perivas-
cular infiltration of monocytoid and centrocytoid cells
next to residual germinal centers with a well-preserved
mantle cuff. Splenic type NMZLs were IgD positive, a fea-
ture that was confirmed in some studies,13,54 but not in oth-
ers.17,48 Unfortunately, not all these studies reported IgD
expression, and it was not reported in relation to growth
pattern.13
Kojima et al. adopted yet another morphological scheme
which recognized a splenic type, MALT type, floral type,
and diffuse large B-cell lymphoma (DLBCL) + MALT
type.17 In their study of 65 patients, the MALT and
DLBCL+MALT type were most frequent (in 45% and
Recognizing nodal marginal zone lymphoma
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Table 1. Clinical characteristics.
Nathwani10 Berger9 Camacho13 Oh14 Traverse- Arcaini16 Kojima17 Mazloom18 Heilgeist19 Olszewski11
et al. et al. et al. et al. Glehen15 et al. et al. et al. et al. et al. et al.
1999c 2000 2003 2006 2006 2007c 2007 2010 2013 2013
N. 20 37 27 36 21 47 65 27 32 4724
M:F 1:1.3 1:1.3 1:1.7 2.6:1 2:1 1:1.8 1:1.2 1:1.7 1.67:1 1:1.12
Age (range) Median 35% over Mean 61 Median Median Median Median 56 Median Median
59 years 60 years years 50 years 54 years 63 years 64 years 67 years 69 years
(26-92) (13-79) (27-83) (29-83) (38-88)
Stage at presentation ≥ III (%) 71 68 41b 47b 76 77 22 59 90b 69b
ECOG score ≥2 (%) NAa 13b NA 17 15b 6 6 0 43b NA
Peripheral lymphadenopathy (%) 100 95 95b NA NA 98 NA NA NA NA
Cervical lymphadenopathy (%) 81 11 NA 56 71 53 86 NA NA NA
B symptoms (%) 14 14 NA 8 10 15 8 8b NA 25b
Bone marrow involvement (%) 28 43b 29b 21b 62 45 0 30 NA NA
Bulky tumor (%) 31 17b NA NA NA 11 NA NA NA NA
Anemia (hemoglobin< 120g/L) (%) NA 31b NA 36 24 11 NA 30 NA NA
Peripheral blood involvement (%) NA 11 10b NA 24 11 NA NA NA NA
LDH elevation 36 40b 43b 20b 48 15 12 22 35b NA
b2-microglobulin elevated (%) NA 33b 41b NA 29 45 NA 38 NA NA
M-protein (%) NA 8 NA NA 33 15 6 NA NA NA
HCV (%) NA NA 20b 5b 0 24b NA NA NA NA
aKarnofsky score ≤70% in 0% of patients; bData not available for all patients. cPercentages instead of number of patients indicated (for a subset of variables). NA: not available; ECOG: Eastern
Cooperative Oncology Group; HCV: hepatitis C virus; LDH: lactate dehydrogenase.
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31%, respectively). The splenic and floral types were pres-
ent in 11% and 14%, respectively. 
A floral variant was also reported by Karube et al. in 6
cases of NMZL.33 These showed a proliferation of medium
sized-cells in the marginal zone that surrounded enlarged
germinal centers with a thick and irregular mantle zone
that sometimes extended into the germinal center, similar
to progressively transformed germinal centers. Rarely,
NMZL with numerous epithelioid histiocytes, hyaline-
vascular Castleman disease-like features, and NMZL in
association with Rosai-Dorfman disease, light and heavy
chain deposition disease, and non-lymphomatous skin
lesions have been reported.55-60 The pattern of bone mar-
row infiltration has been described in only a small number
of cases, with a nodular and paratrabecular pattern in most
cases, followed by an interstitial pattern.15,38,61 One study
reported intrasinusoidal growth, which was the sole pat-
tern present in a single case.38
The impact of centroblasts percentage on prognosis and
the dividing line between DLBCL and NMZL remain
unclear. Some authors diagnosed a case as being trans-
formed if more than 20% of cells were centroblasts, which
rendered a diagnosis of concurrent DLBCL in 20% of
NMZLs.10,62 Two other studies diagnosed DLBCL if more
than 50% of tumor cells were centroblasts, which was
present in 25% and 31%.9,17 Others have been more reluc-
tant to diagnose transformation if large cells are still
admixed with smaller tumor cells.16,63,64 In a study by
Traverse-Glehen and colleagues, the presence of more
than 20% of large cells had no significant effect on prog-
nosis.15 However, as put forward by Kaur, these patients
were mostly treated with aggressive chemotherapy, irre-
spective of large cell percentage.65 This could have pre-
vented the detection of a significant effect of large cell per-
M. van den Brand et al.
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Figure 1. NMZL histology. (A-C).
Hematoxylin and eosin stain,
showing a nodular architecture
on low power (A), with recogniz-
able remnant follicles at higher
power (arrow) (B). In this case,
the lymphoma cells consist of
small cells with scant cytoplasm
and round to indented nuclei
with fine chromatin structure
(lymphocytic/ centrocytic) (C).
Immunohistochemistry shows
BCL2-negative remnant follicles
surrounded by BCL2-positive
lymphoma cells. (D). BCL6 high-
lights the remnant follicles (E).
CD23 shows dendritic networks
that have been partially
destroyed. (F) The tumor cells
show strong expression of
MNDA (G). (H) Strong expression
of IRTA-1 in another case of
NMZL. (I-K) Another case of
NMZL with prominent plasma
cell differentiation, with Russell
bodies (arrow) (I).
Immunohistochemistry against
immunoglobulin light chains
kappa and lambda reveals light
chain restriction for lambda
light chains (J-K).
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GFE
I J K
H
© 
Fe
rra
ta 
St
ort
i F
ou
nd
ati
on
. 
No
 co
mm
erc
ial
 us
e i
s a
ll
we
d
centage. In our own practice, we diagnose transformation
in NMZL only if sheets of large cells are present, similar to
the criterion used in other lymphoma types (Figure 2).66
Immunophenotype
NMZL cells express pan B-cell markers including CD20,
CD79a, and PAX5. The majority of cases are BCL2 posi-
tive, although numbers vary from 43% to 100% of
cases.13,15,33,48,52,54 Most studies report no expression of
BCL6, although one study describes BCL6 staining in a
proportion of cells or large cells only in 43% of cases.15
CD10 positivity has been reported only rarely.54,67 CD5 and
CD23 are usually negative, being reported in 0-17% and
0-29% of cases, respectively.13,15,48,52,54,68 Although studied in
only few patients, the majority of NMZLs appear to
express MUM1.13,15,54 CD43 expression varies between
studies from 5-75%.13,48,52,54 One study detected cyclin D1
expression in 2 of 24 cases, but only in scattered cells and
with a lower intensity than in mantle cell lymphoma.52
Other studies showed no cyclin D1 expression.13,48,54,69
DBA.44 expression has been reported in a subset of
NMZLs in small studies.13,70
The germinal center markers HGAL and LMO2 are
expressed only very rarely in NMZL; only one study
reported expression of these markers in one of 18 and one
of 5 cases, respectively.71 A larger study showed no expres-
sion in 43 cases,48 but in this study, cases with expression
of germinal center markers were excluded from the NMZL
group.
Recently, new positive markers for marginal zone cells
have been reported that could help in the diagnosis of
NMZL. Myeloid cell nuclear differentiation antigen
(MNDA) is expressed by cells of the myelomonocytic lin-
eage, but has also been shown to be expressed by a B-cell
subset that is located around the germinal center and inter-
follicular regions.72 Accordingly, a recent study showed
frequent MNDA expression in NMZL (in 75%), but only
rarely (in 5%) in follicular lymphoma (FL).73
In a similar way, immunoglobulin superfamily receptor
translocation-associated 1 (IRTA1) was shown to be
expressed on marginal zone and monocytoid B cells,74 and
also subsequently on MZLs.75 In the latter study, 73% of
NMZLs were IRTA1-positive in contrast to none of 320
FLs. 
Cytogenetics
Multiple studies have investigated the cytogenetic fea-
tures of NMZL using classical cytogenetics, comparative
genomic hybridization, and fluorescence in situ hybridiza-
tion (FISH). Although numerous cytogenetic abnormalities
have been reported, no specific alterations have been iden-
tified so far. Figure 3 summarizes gains and losses of chro-
mosome regions and whole chromosomes reported in the
literature.12,15,36,76-86 Gains of chromosome 1q, 2p, 3p, 3q, 6p,
and 6q are most frequent, as are losses of 1q and 6q.
Chromosomes 3, 12, and 18 most often show trisomy.
Monosomy is more rarely observed and most frequently
involves chromosomes 9, 13, and 14.
Multiple translocations have been reported in NMZL,
but they do not share a common breakpoint region. This
is in contrast to MALT lymphomas, which frequently
have translocations involving API2, MALT1, BCL10, and
FOXP1. The translocations that have been described in
NMZL do not include regions harboring these
genes.12,15,76,77,79,82,85-89 Although Dierlamm and colleagues did
not detect translocations involving BCL6 in NMZL,12,20,77
the karyotypes of 3 of 21 patients described by Traverse-
Glehen et al. do suggest translocations involving BCL6.15
Molecular features
Gene expression studies in NMZL have generated dif-
ferent results. One study of 16 NMZL and 8 FL cases iden-
tified MNDA as a gene that is differentially expressed
between FL and NMZL, with a rather low ranking of
genes that are known to be expressed more often in FL
than NMZL (e.g. CD10, BCL6).73 Another study of 15
NMZLs and 16 FLs reported a rather homogeneous gene
expression profile in NMZLs resembling marginal zone
and memory B cells.90 Compared to FL, NMZL showed
overexpression of NF-κB-related and -binding genes
Recognizing nodal marginal zone lymphoma
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Figure 2. NMZL with transformation to diffuse
large B-cell lymphoma (DLBCL). (A) Low-grade
component, showing mainly small lymphocytic
cells with scattered histiocytes and only rare
large cells. (B) High-grade component in the
same lymph node, consisting mainly of large
cells that are arranged in sheets, indicating
transformation to DLBCL. (C-D) Ki-67 immuno-
histochemistry shows low proliferative activity in
the low-grade component (C), and high prolifera-
tive activity in the high-grade component (D).
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(TRAF4, CD82), IL-32, histones, members of the TNF
family (TACI, TNFRSF14), and genes involved in lympho-
cyte activation (TGFB1). FLs showed higher expression of
germinal center markers (CD10, BCL6, GCET1, LMO2) in
comparison to NMZL. This study also examined
microRNA profiles; NMZL showed increased expression
of miR-221, miR-223, and let-7f. In FLs, strong expression
of miR-494 was observed. Activation of the NF-κB path-
way is a known feature of extranodal MZL, which is fre-
quently a result of specific translocations or mutations in
NF-κB inhibitors. As discussed above, recurrent NF-κB
activating translocations are not a feature of NMZL, but
inactivating mutations of TNFAIP3, an inhibitor of the NF-
κB pathway, have been shown in 3 of 9 cases of NMZL in
one study.91 This is an interesting finding with potential
diagnostic utility, but needs confirmation in larger studies.
To summarize, there is variability in morphology, pheno-
type, and molecular profile that may be due to either the
variability of the disease itself, or to the variability of the
criteria used for the diagnosis. 
Differential diagnosis
Reactive conditions
Toxoplasmosis and human immunodeficiency virus
(HIV)-associated lymphadenopathy can show hyperplasia
of monocytoid B cells. Morphological differentiation from
NMZL can be difficult in some cases.
Immunohistochemistry can be helpful; normal monocy-
toid B cells are BCL2 negative whereas NMZL cells are
usually BCL2 positive.69,92 If a final diagnosis cannot be
made by morphology and immunohistochemistry, clonal-
ity testing can provide important additional information.93
Follicular lymphoma
The classical case of FL is easily distinguished from
NMZL, but areas of overlap exist. First, some FLs grow in
a marginal zone pattern resembling NMZL. In addition,
NMZLs frequently show follicular colonization that can
cause resemblance to FL. In follicular colonization, the
lymph node retains a nodular architecture on low power.
The BCL2 positive NMZL cells that infiltrate the germinal
M. van den Brand et al.
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Figure 3. Cytogenetics. Overview of cytogenetic abnormalities in
NMZL. (A) Overview of chromosomal gains (top, in green) and loss-
es (bottom, in red). Results for the small arm (p, left) and long arm
(q, right) are indicated separately. (B) Overview of trisomies (top,
green) and monosomies (bottom, red). Results represent an aggre-
gation of data from multiple studies, comprising 100
patients.12,15,36,76-83,85,86 For most patients (n=75), all detected kary-
otypic abnormalities were reported. In one CGH study with 25
patients, only recurrent gains (in ≥4 cases) were reported.81 For
monosomies and trisomies of chromosomes 3, 7, and 12, an addi-
tional study of 12 patients has been included.84
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centers falsely suggest BCL2-positive follicles. The resid-
ual follicular cells in the background give a false impres-
sion of BCL6- and CD10-positivity. Accordingly, an erro-
neous diagnosis of FL is easily made. The key to solving
this problem lies in careful review at high power which
shows BCL2-negative centroblasts and centrocytes that
express BCL6 and CD10, with the truly neoplastic BCL2-
positive cells in between (Figure 4). Another clue for the
presence of pre-existent rather than neoplastic germinal
centers comes from a high proliferative index as shown by
immunohistochemistry for Ki-67. 
In the majority of cases, demonstration of a transloca-
tion involving BCL2 will help in diagnosing FL, but
approximately 10% of FLs do not have this translocation.
At present there are no good criteria by which t(14;18)
negative follicular lymphoma can be separated from
NMZL with complete follicular colonization. Therefore,
in some cases, a definitive diagnosis cannot be made. New
immunohistochemical markers could further reduce this
ambiguous group (also discussed under
“Immunophenotype”). 
LMO2 and HGAL are germinal center markers that are
frequently positive in FL. MNDA and IRTA have recently
been identified as markers of MZL, although both have
only been reported in single studies (see above). With flow
cytometry, the junctional adhesion molecule C (JAM-C)
has been shown to be expressed in the large majority of
MZLs, but not in FLs. This is a potentially interesting find-
ing, although it needs confirmation in larger studies with
specification of the specific subtypes of MZL.94
Extranodal marginal zone lymphoma
By definition, the distinction of NMZL from lymph
node involvement by EMZL must be made by a thorough
clinical search for extranodal disease (Figure 5A and B).
However, some features suggest a primary extranodal
lymphoma. Pure monocytoid morphology is more typical
of MALT lymphoma than NMZL. In addition, EMZL fre-
quently have specific translocations involving BCL10 and
MALT1, which have not been reported in NMZL. 
Splenic MZL (SMZL) only rarely presents with lym-
phadenopathy. It virtually always infiltrates the bone mar-
row with a characteristic intertrabecular and intrasinu-
soidal pattern, which is not typical of NMZL (Figure 5C
and D). IgD negativity is an argument against SMZL.
Approximately 40% of splenic MZLs have a loss of chro-
mosome 7q, which is present in less than 5% of NMZLs.
Lymphoplasmacytic lymphoma
NMZL and lymphoplasmacytic lymphoma (LPL) are
both low-grade B-cell lymphomas with a morphology
ranging from lymphocytes to plasma cells, making distinc-
tion between these entities problematic in some cases.
Again, it is important to take clinical features into account;
LPL generally presents in the bone marrow with hypervis-
cosity (Waldenströms macroglobulinemia), whereas
NMZL generally present with lymphadenopathy.
However, especially in lymph nodes, differentiation can
be difficult or impossible. Arguments in favor of NMZL
include monocytoid cellular morphology, a marginal zone
growth pattern, and follicular colonization. LPL classically
shows (partial) retention of the architecture with dilated
sinuses, although other patterns frequently occur. We feel
that the use of three diagnostic categories (i.e. NMZL, LPL,
and ambiguous: low-grade B-cell lymphoma with plasma-
cytic differentiation) is a sensible approach to this diagnos-
tic problem. The recent discovery of L265P hotspot muta-
tions in MYD88 in the large majority of LPLs but not in
MZLs is of great potential use for the differential diagnosis
between LPL and NMZL.95 This is illustrated by a case we
had classified as NMZL but was shown to carry a L265P
mutation in MYD88. Subsequent evaluation indeed
revealed clinical features of Waldenströms macroglobu-
linemia leading to a diagnosis of LPL rather than NMZL.
Other B-cell lymphomas
Mantle cell lymphoma sometimes resembles NMZL
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Figure 4. Follicular colonization. A single section
was sequentially stained with multiple antibodies,
allowing assessment of the expression of multiple
proteins in the same section. (A) A pre-existent
germinal center is present in the bottom-left cor-
ner, which is highlighted by BCL6 staining. (B) The
germinal center cells are BCL2 negative, whereas
the infiltrating lymphoma cells are BCL2 positive.
(C) MNDA expression largely overlaps with BCL2
expression, confirming that indeed the lymphoma
cells are the BCL2 positive cells. (D) Ki-67 high-
lights the pre-existent germinal center similar to
the BCL6 stain, indicating that the proliferative
activity is high in the germinal center cells, but low
in lymphoma cells.
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morphologically. It can be reliably distinguished from
NMZL by its positivity for CD5 and cyclin D1, and the
presence of a CCND1 translocation. Similarly, chronic
lymphocytic leukemia differs from NMZL by its expres-
sion of CD5 and CD23.
NMZL frequently contains significant numbers of cen-
troblasts, which can cause confusion with diffuse large B-
cell lymphoma (DLBCL). A clear boundary between
NMZL and DLBCL has not been established. In our own
practice, we only diagnose transformation to DLBCL if
sheets of blasts are present without interspersed smaller
tumor cells. 
Pediatric nodal marginal zone lymphoma
In 2003, Taddese-Heath and colleagues recognized a
pediatric subtype of NMZL.96 Characteristic features were
a striking male predominance and an indolent disease
course. In contrast to NMZL in adults, pediatric NMZLs
presented with only localized disease, corresponding with
an excellent prognosis. Of note, ‘pediatric NMZL’ might
also occur in (young) adults; patients up to 44 years of age
have been reported.97 Histologically, pediatric NMZL was
frequently associated with progressively transformed ger-
minal center-like changes (in 66%), which is not a feature
of adult NMZL. Cytogenetic abnormalities that character-
ize adult EMZL have only been rarely observed in pedi-
atric MZL, with trisomy 18 and trisomy 3 as the most fre-
quent aberrations.98 There are no data regarding the
expression of IRTA1 and MNDA. Based on these features,
it seems relevant to keep the pediatric lesions separate
from adult NMZL, and to try to find markers for both. 
Treatment and prognosis
There is currently no consensus on how to treat NMZL
patients. Usually, guidelines for follicular lymphoma or
chronic lymphocytic leukemia/ small lymphocytic lym-
phoma are adopted.99 Different studies have reported dif-
ferent (combinations of) treatments, including watchful
waiting, surgery, radiotherapy, different chemotherapeu-
tic regimens, rituximab, and autologous stem cell trans-
plantation.9,13-19 However, no optimal treatment strategy
can be deduced from these studies. Complete response is
achieved in 55-74% of patients.9,14-18 
A phase II study in 26 patients with marginal zone lym-
phomas, mostly NMZLs, illustrated that treatment regi-
mens in other low-grade B-cell lymphomas cannot be sim-
ply applied to MZL.100 Although treatment with fludara-
bine and rituximab was highly effective, it came with sig-
nificant toxicity that had not been observed in other lym-
phoma types to that extent. 
Five-year overall survival rates range from 64-89%.11,14-19
The FLIPI (Follicular Lymphoma International Prognostic
Index) has been reported to predict overall survival16 and
progression-free survival14 for patients with NMZL, but
this could not be confirmed for the NMZL subgroup in a
recent study with 32 NMZL patients.19 Age, the presence
of B symptoms, Ann Arbor stage, anemia, performance
score, sex, race, and chemotherapy were associated with
progression-free survival or event-free survival in multi-
variate analyses.11,14,16 
It is clear that a better understanding of this lymphoma
type is needed in order to select these patients for newer,
targeted therapies and to improve outcome. 
Conclusions and recommendations
Nodal marginal zone lymphoma remains an enigmatic
entity with accompanying difficulties in diagnosis and a
lack of knowledge of prognosis and treatment. Because of
its rarity, it is hard to obtain large study groups. Also,
because NMZL is frequently a diagnosis of exclusion, the
series that have been studied might contain a somewhat
heterogeneous group of low-grade B-cell lymphomas.
Nevertheless, progress is being made; recent studies have
identified positive markers for MZL (i.e. MNDA and
IRTA1), and gene expression studies have identified a spe-
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Figure 5. Extranodal and splenic mar-
ginal zone lymphoma. (A and B).
Extranodal marginal zone lymphoma
of the parotid gland, showing the typi-
cal lymphoepithelial lesions; hema-
toxylin and eosin stain shows infiltra-
tion and destruction of glandular
epithelium (A), which is highlighted by
immunohistochemical staining of lym-
phoma cells with anti-CD20 (B). (C and
D): bone marrow involvement of
splenic marginal zone lymphoma.
Hematoxylin and eosin stain shows
scattered strands of lymphoid cells in a
background of pre-existent
hematopoiesis (C). The typical sinu-
soidal pattern of infiltration is high-
lighted by CD20 staining (D), which
shows strands of lymphoid cells with a
somewhat rounded contour.
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cific gene expression profile that separates NMZL from
other lymphoma types. 
In routine practice, the diagnosis of NMZL can be
established on the basis of the criteria described above
and by excluding other lymphoma entities. As we have
indicated, in some cases, this probably results in misdiag-
nosis; not a big problem since prognosis and treatment
are quite similar. However, as more and more targeted
treatments are becoming available, better knowledge of
the pathogenesis of NMZL will be necessary to deter-
mine which targeted pharmaceuticals will be of benefit
to affected patients. 
To improve understanding of this disease, series that are
being investigated for pathological criteria and clinical fea-
tures will need very rigorous exclusion of cases, including
molecular testing and inclusion of complete clinical data.
By doing that, the group of cases in a study may become
rather small, but there will be a greater chance of finding
relevant new data. 
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